ProSomnus intraoral medical devices are engineered to precisely track the treatment plan and anatomy for each patient. Non-invasive, patient preferred and easy to use, ProSomnus devices have ...
PLEASANTON, Calif., July 06, 2023 (GLOBE NEWSWIRE) -- ProSomnus, Inc. (NASDAQ: OSA), a leading CPAP alternative for the treatment of Obstructive Sleep Apnea ("OSA"), will report its strong second ...
Obstructive Sleep Apnea treatment provider ProSomnus Inc OSA reported Q2 revenues of $6.9 million, up 43% Y/Y and a sequential revenue increase of 19%, slightly beating the consensus of $6.4 million.
ProSomnus is honored to partner with Lovell to expand access to Precision Oral Appliance Therapy for the millions of Veterans with Obstructive Sleep Apnea.” — Len Liptak, CEO, ProSomnus Sleep ...
PLEASANTON, Calif., Feb. 22, 2024 (GLOBE NEWSWIRE) -- ProSomnus, Inc. (NASDAQ: OSA) (the “Company”), the leading non-CPAP Obstructive Sleep Apnea (OSA) therapy™, announced results of its pilot study ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results